FDA revised draft guidance for generics of Eli Lilly's Zepbound & Novo Nordisk's Ozempic, addressing concerns about safety of compounded GLP-1s.
The FDA revised its draft guidance for generic companies looking to develop copycats of some of the world’s best-selling weight loss drugs, including Eli Lilly’s …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1…
Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound…
The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from…
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts…
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for…
